Lin Chen1, Lixin Li1, Zhuochun Huang1, Qian Niu1, Fengyu Huang2, Junlong Zhang1, Bin Yang1, Lanlan Wang3. 1. Department of Laboratory Medicine, West China Hospital, Chengdu 610041, China. 2. West China Clinical Medical School, Sichuan University, Chengdu 610041, China. 3. Department of Laboratory Medicine, West China Hospital, Chengdu 610041, China. *Corresponding author, E-mail: WangLL87@126.com.
Abstract
OBJECTIVE: To explore the roles of bone metabolism-related molecules in bone metabolic disturbance and disease progression of patients with rheumatoid arthritis (RA). METHODS: A total of 66 RA patients and 20 healthy controls were included, and their relevant clinical information was gathered. Electrochemiluminescence immunoassay (ECLIA) was used to detect the levels of osteocalcin N-terminal middle (OC-N-MID) and C-terminal cross-linked telopeptides of type 1 collagen (CTX) in serum. The serum levels of Wnt inhibitory factor Dickkopf1 (DKK1) and receptor activator of nuclear factor-κB ligand (RANKL) were determined by magnetic luminex assays. Flow cytometry was used to detect the RANKL level on peripheral blood T cells. RESULTS: Compared with healthy controls, the levels of OC-N-MID and CTX in the sera of the RA patients showed no significant difference. Level of RANKL in the sera of the RA patients was higher than that in the controls, while level of DKK1 was lower. The level of RANKL on peripheral blood T cells increased in the RA patients, especially on CD3(+) T cells. CONCLUSION: In RA patients, level of RANKL on T cells is elevated, and the serum level of RANKL increases, but DKK1 decreases.
OBJECTIVE: To explore the roles of bone metabolism-related molecules in bone metabolic disturbance and disease progression of patients with rheumatoid arthritis (RA). METHODS: A total of 66 RApatients and 20 healthy controls were included, and their relevant clinical information was gathered. Electrochemiluminescence immunoassay (ECLIA) was used to detect the levels of osteocalcin N-terminal middle (OC-N-MID) and C-terminal cross-linked telopeptides of type 1 collagen (CTX) in serum. The serum levels of Wnt inhibitory factor Dickkopf1 (DKK1) and receptor activator of nuclear factor-κB ligand (RANKL) were determined by magnetic luminex assays. Flow cytometry was used to detect the RANKL level on peripheral blood T cells. RESULTS: Compared with healthy controls, the levels of OC-N-MID and CTX in the sera of the RApatients showed no significant difference. Level of RANKL in the sera of the RApatients was higher than that in the controls, while level of DKK1 was lower. The level of RANKL on peripheral blood T cells increased in the RApatients, especially on CD3(+) T cells. CONCLUSION: In RApatients, level of RANKL on T cells is elevated, and the serum level of RANKL increases, but DKK1 decreases.